World Sleep Industry ENCYCLOPEDIA

Anshen Bunao Liquid

2.1.2

Finished-product identity and seven components

Anshen Bunao Liquid is the name of a registered Chinese patent-medicine oral liquid and is indexed under WSIC 2.1.2. Its pharmacopoeial formula contains deer velvet, processed Polygoni Multiflori Radix, Epimedium, dried ginger, licorice, jujube fruit, and vitamin B1. It therefore combines an animal-derived medicinal material, processed herbal medicines, and a specifically labelled vitamin. Its registered traditional functions are described as replenishing essence and marrow, benefiting qi and blood, strengthening the brain, and calming the spirit. The labelled symptom cluster covers dizziness, fatigue, forgetfulness, and insomnia attributed to deficiency of kidney essence and of qi and blood, including neurasthenia presenting with that cluster.

It is distinct from Zaoren Anshen Liquid, Anshen Bunao capsules or tablets, single-ingredient processed Polygonum multiflorum, a vitamin B1 supplement, and a homemade tonic formula. A similar name or the shared words “calming the spirit” do not make formulas, processing, extraction, quality standards, or risks the same. Millilitres of liquid cannot be converted directly into tablets, capsules, or grams of crude herb. The presence of vitamin B1 does not demonstrate that every symptom is caused by vitamin deficiency or turn the combination into an ordinary nutritional drink.

Nonprescription status and labelled scope

In China, a specifically authorized Anshen Bunao Liquid may be regulated as a nonprescription medicine. An OTC mark means that it can be purchased under the applicable local framework. It does not authorize long-term use outside the current leaflet, establish suitability for every form of insomnia, or exclude serious adverse effects. The nonproprietary name, approval number, marketing authorization holder, dosage form, unit size, and leaflet revision should be checked together. An online title, similar package, reputation, or “tonic” claim cannot establish medicine identity.

Excipients, packaging, shelf life, and warnings may differ among authorization holders and presentations, so follow only the product in hand. Some current labels list sucrose, benzoic acid, sodium benzoate, ethanol, and purified water; they also advise against use during a febrile cold and call for professional guidance in severe chronic disease and for children, pregnancy, breastfeeding, or frail older people. Whether to take it after food, the permitted duration, and handling after opening should come from that package rather than another brand or an old web page.

Traditional pattern and the “brain tonic” boundary

Deficiency of kidney essence and of qi and blood is a traditional diagnostic framework. Dizziness, fatigue, forgetfulness, and insomnia are a registered cluster, not a pattern established automatically by any one symptom. Inadequate sleep opportunity, shift work and circadian misalignment, anemia, thyroid disease, pain, medicines or substances, anxiety or depression, and sleep-related breathing disorders can produce similar complaints. The label term “neurasthenia” likewise does not replace assessment of symptom duration, daytime function, and modern sleep or mental-health diagnoses.

“Strengthening the brain” in the name and traditional function does not prove enhancement of intelligence, attention, or examination performance in a healthy person. Nor does it establish prevention or treatment of dementia, Alzheimer disease, stroke, or another neurological disorder. Animal experiments on memory, fatigue, anxiety-like behavior, or gut microbiota are mechanistic exploration; they cannot directly demonstrate cognitive enhancement, sleep efficacy, or long-term disease outcomes in humans.

Clinical evidence and outcome interpretation

The published clinical literature includes small studies comparing Anshen Bunao Liquid with active medicines such as estazolam and a network meta-analysis in which it was combined with nonbenzodiazepine medicines. Some reports favor short-term “total effectiveness” or symptom-scale outcomes, but studies often lack a credible placebo, adequate blinding, preregistration, objective sleep measures, and long follow-up. A combination result also does not demonstrate that the oral liquid works alone or reduces the risks of the other medicine.

A “total effectiveness rate,” traditional symptom score, Pittsburgh Sleep Quality Index, sleep diary, actigraphy, and polysomnography are different outcomes and cannot substitute for one another. Brand, lot, authorization holder, formula version, comparator, and population further constrain transferability. The present evidence does not establish that this product is generally equivalent or safer than prescription hypnotics, remodels sleep architecture, or can be maintained long term without reassessment.

Quality, excipients, and use checks

Before purchase, check the approval number, medicine traceability information, unit or bottle volume, labelled vitamin B1 amount, lot, expiry, storage instructions, and seal integrity. Pharmacopoeial identification, content, and mixture tests are manufacturing and release requirements; they do not predict personal clinical benefit. Sucrose, ethanol, and preservatives can matter in diabetes, alcohol restriction, allergy, or dietary constraints, so suitability cannot be assessed from the six medicinal materials alone.

A label that permits “a small amount of sediment after standing” does not make every layer, floc, or color change normal. Compare the exact product's stated color, odor, and appearance. Stop use after a broken seal, leak, bulging container, unusual odor or sediment, expiry, or loss of required storage conditions, retain the lot, and ask a pharmacist, authorization holder, or regulator. Do not filter, dilute, or boil the liquid and then continue using it, and do not apply an unopened expiry date to a remainder after opening.

Adverse effects, hepatic risk, and interactions

Postmarketing monitoring has reported nausea, vomiting, abdominal discomfort, dry mouth, abdominal pain or distension, diarrhea, constipation, headache, somnolence, rash, itching, palpitations, allergic reactions, and abnormal liver biochemistry. The contraindication for a history of liver disease or abnormal liver tests must be followed. Processing Polygonum multiflorum changes composition and risk but does not establish freedom from hepatotoxicity. Generalized weakness, loss of appetite, aversion to oily food, nausea, upper abdominal discomfort, dark urine, or yellowing of the eyes or skin requires immediate discontinuation and medical review. Breathing difficulty, swelling of the face, lips, or tongue, syncope, or altered consciousness requires emergency care.

The exact label also warns against use with certain alkaline medicines, tannin-containing traditional medicines or foods, and products containing Sargassum, Euphorbia pekinensis, Euphorbia kansui, Knoxia valerianoides, or Daphne genkwa. The formula additionally contains licorice, processed Polygonum multiflorum, Epimedium, and ethanol. Give a physician or pharmacist the complete list of prescription medicines, OTC drugs, herbs, supplements, and alcohol exposure so that duplicate herbs and unpredictable interactions can be reviewed. Do not drive or operate hazardous equipment if somnolent, and do not assume that spacing products by a few hours eliminates an interaction.

Seven-day reassessment and sleep-medicine boundary

During a short, label-concordant trial, change only one product at a time. Do not add more after a missed administration, a night without improvement, or in preparation for an examination, and do not stack another dosage form with the same name or another sleep combination. Record administration, lights-out, estimated sleep onset, awakenings, rising time, next-day function, and adverse effects. A current finished-product label directs medical review if symptoms have not improved after seven days and says not to exceed directions or continue for the long term; the package in hand remains controlling.

Persistent or recurrent insomnia, substantial daytime impairment, loud snoring or witnessed breathing pauses, morning headache, restless-legs-type symptoms, abnormal sleep behavior, manic-type activation, progressive cognitive change, severe depression, or self-harm risk requires the appropriate sleep, medical, neurological, or mental-health assessment. Multicomponent cognitive behavioral therapy for insomnia is first-line treatment for chronic insomnia in adults. Anshen Bunao Liquid does not replace that treatment, adequate sleep opportunity, testing for sleep apnea, or emergency care.